Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG & ASHG Presidents’ Sign-on Letter to Congress Concerning Patent Eligibility Reform
-
Group Sign-on Letter to Congress Opposing Proposed Amendments to Section 101 of the Patent Act
-
ACMG Comments to CMS Regarding NCD 90.2 and Medicare Coverage of NGS for Advanced Cancer
-
Group Sign-on Letter to CMS Requesting Extension of Comment Period Regarding NGS Coverage Reconsideration
-
ACMG Letter to Congress Regarding the Advancing Access to Precision Medicine Act
-
Group Sign-on Letter to CMS Requesting Revision of Interpretation of NCD for NGS for Advanced Cancer
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations
-
ACMG Comments to CMS on Proposed NCD for Coverage of NGS for Medicare Beneficiaries with Advanced Cancer (CAG-00450N)
-
ACMG Response to Expansion of Direct-to-Consumer Genetic Testing
-
ACMG Letter to Congress Supporting the Accurate Education for Prenatal Screenings Act (HR 3441)